This time, to my great delight, I was joined in the CT waiting area by my dear former fellow, who happened to be at NIH for a visit that day. To be polite I offered him some of my oral contrast, but he wisely declined.
Pro Tip: Crystal Light On the Go packets make iohexol (oral contrast) much, MUCH more palatable. I highly recommend the wild strawberry flavor.
Also this visit: I finally got to meet the person whose news story led me to the NIH. She was the first patient with solid tumors who responded to TIL therapy back in 2014. We had been in contact many times before, but had never met in person--until this visit!
We even took a photo with The Guy, himself.
Here we see Responder 2 (me), The Guy, and Responder 1 together for the first time.
|OP3 at NIH--August 21, 2018|
But wait, there's more! Here's a link to an article that mentions my case:
Moderna thinks the immune system can be recruited to help fight KRas where small-molecule drugs have failed. In 2016, researchers at the National Cancer Institute reported on discovering a person whose immune system developed a T-cell response to cancers with KRas... “That was really the watershed moment for the field,” says Tal Zaks, Moderna’s chief medical officer.